Table 1. Characteristics of the included studies.
| Study | Country | Period | Regimen | Duration | Genotypes | Types of Analysis | Non-specialized personnel characteristics | Type of support from specialists (when available) | Specialized personnel characteristics (when the comparison is available) |
|---|---|---|---|---|---|---|---|---|---|
| Jayasekera et al 2015[22] | USA | Dec-2013 | SOF /RBV | 12 or 24 weeks | GT1 | ITT and per-protocol | Part-time licensed vocational nurse (mid-level provider) | Pre and post-treatment assessments, and referral by a clinical need | NA |
| GT2 | |||||||||
| GT3 | |||||||||
| GT4 | |||||||||
| Nov-2014 | SOF/SIM | ||||||||
| Capileno et al 2017[20] | Pakistan | Feb-2015 | SOF /RBV | 12 or 24 weeks | GT2 | ITT | Mid-level health practitioners | NA | NA |
| Dec-2015 | GT3 | ||||||||
| GT4 | |||||||||
| Kattakuzhy et al 2017[23] | USA | Jan-2015 | SOF/LDV | 12 weeks | GT1 | ITT | Licensed nurse practitioner or physician board-certified in family or internal medicine | NA | Specialist (infectious diseases or gastroenterology or hepatology) |
| Nov-2015 | |||||||||
| Lasser et al 2017[11] | USA | Mar-2015 | NA | NA | NA | ITT and per-protocol | Primary care physicians | Telephone and electronic messaging | NA |
| Apr-2016 | |||||||||
| Baker et al 2018[27] | Australia | Mar-2016 | SOF/DCV | NA | GT1 | ITT and per-protocol | General practitioners | Consultation with specialist | NA |
| Apr-2016 | SOF/LDV | GT3 | |||||||
| Gupta et al 2018[28] | Rwanda | Feb-2017 | SOF/LDV | 12 weeks | GT1 | ITT and per-protocol | Non-specialist clinicians, internists, general practitioner, nurses and social workers | Supervision and mentoring by one internist with specialized HCV training | NA |
| Sep-2018 | GT4 | ||||||||
| Lee et al 2018[24] | Australia | Feb-2016 | SOF /RBV | NA | GT1 | Per-protocol | General practitioners, sexual health physicians, general physicians, and substance use service | Phone or email support and education sessions | Gastroenterologists |
| SOF/DCV | GT2 | ||||||||
| GT3 | |||||||||
| SOF/LDV | GT4 | ||||||||
| Dec-2017 | Others | ||||||||
| SOF/VEL | |||||||||
| Nouch et al 2018[25] | Canada | Oct-2015 | SOF /RBV | NA | GT1 | ITT and per-protocol | Family doctors | Visit with a specialist when needed | NA |
| SOF/LDV ± RBV | GT2 | ||||||||
| Oct-2017 | GT3 | ||||||||
| SOF/VEL | GT4 | ||||||||
| Wade et al 2018[10] | Australia | July-2015 | SOF /RBV | NA | GT1 | ITT and per-protocol | General practitioners | Remote specialist consultation | Specialist (infectious diseases or gastroenterology or hepatology) |
| SOF/DCV | |||||||||
| SOF/LDV | |||||||||
| Jun-2017 | GT3 |
USA, United States of America; SOF, sofosbuvir; RBV, ribavirin; SIM, simeprevir; LDV, ledipasvir; DCV, daclatasvir; VEL, velpatasvir; NA, not available; GT, genotype; ITT, intention to treat.